Therapeutic Response

CD20 + status confers therapeutic sensitivity to Rituximab in patients with Non-Hodgkin Lymphoma.

Statements

Source and description
Rituxan (rituximab) [package insert]. FDA. The U.S. Food and Drug Administration granted approval to rituximab for the treatment of adult patients with relapsed or refractory, low grade or follicular, CD20-positive B-cell Non-Hodgkin's Lymphoma (NHL).
Rituxan (rituximab) [product monograph]. HC. Health Canada approved rituximab for the treatment of patients with relapsed or refractory low-grade or follicular, CD20 positive, B-cell non-Hodgkin's lymphoma.